Assay for fatty acid amide hydrolase activity / C. Rakers et al. / Anal. Biochem. 421 (2012) 699–705
3] P. Pacher, S. Batkai, D. Osei-Hyiaman, L. Offertaler, J. Liu, J. Harvey-White, A. [15] M. Maccarrone, M. Bari, A.F. Agro,
705
[
A
sensitive and specific
Brassai, Z. Jarai, B.F. Cravatt, G. Kunos, Hemodynamic profile, responsiveness to
anandamide, and baroreflex sensitivity of mice lacking fatty acid amide
hydrolase, Am. J. Physiol. Heart Circ. Physiol. 289 (2005) H533–H541.
radiochromatographic assay of fatty acid amide hydrolase activity, Anal.
Biochem. 267 (1999) 314–318.
[16] O. Mrklas, A. Chu, S. Lunn, Determination of ethanolamine, ethylene glycol,
and triethylene glycol by ion chromatography for laboratory and field
biodegradation studies, J. Environ. Monit. 5 (2003) 336–340.
[
[
4] A.H. Lichtman, C.C. Shelton, T. Advani, B.F. Cravatt, Mice lacking fatty acid
amide hydrolase exhibit
a cannabinoid receptor-mediated phenotypic
[17] K. Guo, L. Li, Differential12C-/ C-isotope dansylation labeling and fast liquid
chromatography/mass spectrometry for absolute and relative quantification of
the metabolome, Anal. Chem. 81 (2009) 3919–3932.
13
hypoalgesia, Pain 109 (2004) 319–327.
5] S. Holt, F. Comelli, B. Costa, C.J. Fowler, Inhibitors of fatty acid amide hydrolase
reduce carrageenan-induced hind paw inflammation in pentobarbital-treated
mice: comparison with indomethacin and possible involvement of
cannabinoid receptors, Br. J. Pharmacol. 146 (2005) 467–476.
6] K. Ahn, D.S. Johnson, M. Mileni, D. Beidler, J.Z. Long, M.K. McKinney, E.
Weerapana, N. Sadagopan, M. Liimatta, S.E. Smith, S. Lazerwith, C. Stiff, S.
Kamtekar, K. Bhattacharya, Y. Zhang, S. Swaney, B.K. Van, R.C. Stevens, B.F.
Cravatt, Discovery and characterization of a highly selective FAAH inhibitor
that reduces inflammatory pain, Chem. Biol. 16 (2009) 411–420.
[18] S. Spanner, G.B. Ansell, The determination of free ethanolamine in brain tissue
and its release on incubation, J. Neurochem. 30 (1978) 497–498.
[19] A.A. Zoerner, F.M. Gutzki, S. Batkai, M. May, C. Rakers, S. Engeli, J. Jordan, D.
Tsikas, Quantification of endocannabinoids in biological systems by
chromatography and mass spectrometry: a comprehensive review from an
analytical and biological perspective, Biochim. Biophys. Acta 1811 (2011) 706–
723.
[
[
7] S. Batkai, P. Pacher, D. Osei-Hyiaman, S. Radaeva, J. Liu, J. Harvey-White, L.
Offertaler, K. Mackie, M.A. Rudd, R.D. Bukoski, G. Kunos, Endocannabinoids
acting at cannabinoid-1 receptors regulate cardiovascular function in
hypertension, Circulation 110 (2004) 1996–2002.
8] S. Engeli, J. Bohnke, M. Feldpausch, K. Gorzelniak, J. Janke, S. Batkai, P. Pacher, J.
Harvey-White, F.C. Luft, A.M. Sharma, J. Jordan, Activation of the peripheral
endocannabinoid system in human obesity, Diabetes 54 (2005) 2838–2843.
9] M. Bluher, S. Engeli, N. Kloting, J. Berndt, M. Fasshauer, S. Batkai, P. Pacher, M.R.
Schon, J. Jordan, M. Stumvoll, Dysregulation of the peripheral and adipose
tissue endocannabinoid system in human abdominal obesity, Diabetes 55
[20] C.J. Hillard, D.M. Wilkison, W.S. Edgemond, W.B. Campbell, Characterization of
the kinetics and distribution of N-arachidonylethanolamine (anandamide)
hydrolysis by rat brain, Biochim. Biophys. Acta 1257 (1995) 249–256.
[21] S. Maurelli, T. Bisogno, L. De Petrocellis, A. Di Luccia, G. Marino, V. Di Marzo,
Two novel classes of neuroactive fatty acid amides are substrates for mouse
neuroblastoma ‘‘anandamide amidohydrolase’’, FEBS Lett. 377 (1995) 82–
86.
[22] Y. Wang, F. Ramirez, G. Krishnamurthy, A. Gilbert, N. Kadakia, J. Xu, G.
Kalgaonkar, M.K. Ramarao, W. Edris, K.E. Rogers, P.G. Jones, High-throughput
screening for the discovery of inhibitors of fatty acid amide hydrolase using
a microsome-based fluorescent assay, J. Biomol. Screen. 11 (2006) 519–
527.
[23] S. Holt, J. Nilsson, R. Omeir, G. Tiger, C.J. Fowler, Effects of pH on the inhibition
of fatty acid amidohydrolase by ibuprofen, Br. J. Pharmacol. 133 (2001) 513–
520.
[24] M.P. Patricelli, H.A. Lashuel, D.K. Giang, J.W. Kelly, B.F. Cravatt, Comparative
characterization of a wild type and transmembrane domain-deleted fatty acid
amide hydrolase: identification of the transmembrane domain as a site for
oligomerization, Biochemistry 37 (1998) 15177–15187.
[
[
(
2006) 3053–3060.
[
10] N. Battista, M. Bari, A. Tarditi, C. Mariotti, A.C. Bachoud-Levi, C. Zuccato, A.
Finazzi-Agro, S. Genitrini, M. Peschanski, S. Di Donato, E. Cattaneo, M.
Maccarrone, Severe deficiency of the fatty acid amide hydrolase (FAAH)
activity segregates with the Huntington’s disease mutation in peripheral
lymphocytes, Neurobiol. Dis. 27 (2007) 108–116.
11] M.K. Ramarao, E.A. Murphy, M.W. Shen, Y. Wang, K.N. Bushell, N. Huang, N.
Pan, C. Williams, J.D. Clark, A fluorescence-based assay for fatty acid amide
hydrolase compatible with high-throughput screening, Anal. Biochem. 343
[
[
(
2005) 143–151.
[25] V. Di Marzo, T. Bisogno, T. Sugiura, D. Melck, L. De Petrocellis, The novel
endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal-
and basophil-like cells: connections with anandamide, Biochem. J. 331 (1998)
15–19.
[26] K. Ahn, S.E. Smith, M.B. Liimatta, D. Beidler, N. Sadagopan, D.T. Dudley, T.
Young, P. Wren, Y. Zhang, S. Swaney, B.K. Van, J.L. Blankman, D.K. Nomura, S.N.
Bhattachar, C. Stiff, T.K. Nomanbhoy, E. Weerapana, D.S. Johnson, B.F. Cravatt,
Mechanistic and pharmacological characterization of PF-04457845: a highly
potent and selective fatty acid amide hydrolase inhibitor that reduces
inflammatory and noninflammatory pain, J. Pharmacol. Exp. Ther. 338
(2011) 114–124.
12] A.A. Zoerner, S. Batkai, M.T. Suchy, F.M. Gutzki, S. Engeli, J. Jordan, D. Tsikas,
Simultaneous UPLC–MS/MS quantification of the endocannabinoids 2-
arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide
in human plasma: Minimization of matrix effects, 2AG/1AG isomerization, and
B (in press)
[
[
13] D.L. Boger, H. Sato, A.E. Lerner, M.P. Hedrick, R.A. Fecik, H. Miyauchi, G.D.
Wilkie, B.J. Austin, M.P. Patricelli, B.F. Cravatt, Exceptionally potent inhibitors
of fatty acid amide hydrolase: the enzyme responsible for degradation of
endogenous oleamide and anandamide, Proc. Nat. Acad. Sci. U.S.A. 97 (2000)
044–5049.
14] D.G. Deutsch, S.A. Chin, Enzymatic synthesis and degradation of
anandamide, cannabinoid receptor agonist, Biochem. Pharmacol. 46
1993) 791–796.
5
[27] U. Yapa, J.J. Prusakiewicz, A.D. Wrightstone, L.J. Christine, J. Palandra, E.
Groeber, A.J. Wittwer, High-performance liquid chromatography-tandem mass
spectrometry assay of fatty acid amide hydrolase (FAAH) in blood: FAAH
inhibition as clinical biomarker, Anal. Biochem. 421 (2012) 556–565.
a
(